HALO Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 06, 2023|
Current P/E* ratio: 22.30 | Price (Sep 22, 2023, EOD): $39.57
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for HALO Premium
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules a... HALO Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.